APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Monoclonal Antibodies

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Selected research

Industry Research

Biosimilar Monoclonal Antibodies Industry Research Report 2026

Report ID 173970940521 December 2025121 pages

Choose your research edition.

Industry ResearchBiosimilar Monoclonal Antibodies Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Biosimilar Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Monoclonal Antibodies Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Monoclonal Antibodies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.

Read the full market overview

Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

Report Scope

This report quantifies the global Biosimilar Monoclonal Antibodies market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Biosimilar Monoclonal Antibodies Market by Company

Celltrion

Pfizer (Hospira)

3SBIO

Novartis (Sandoz)

Dr Reddy’s

Celgen Biopharma

Cadila Healthcare

Hisun Pharma

Torrent Pharmaceuticals

Biosimilar Monoclonal Antibodies Segment by Type

Infliximab

Rituximab

Trastuzumab

Adalimumab

Other

Biosimilar Monoclonal Antibodies Segment by Application

Oncology

Autoimmune Disease

Other

Biosimilar Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Biosimilar Monoclonal Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Biosimilar Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Biosimilar Monoclonal Antibodies Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Biosimilar Monoclonal Antibodies Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2021-2026) Table 8. Global Biosimilar Monoclonal Antibodies Revenue of Manufacturers (2021-2026) Table 9. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Biosimilar Monoclonal Antibodies Average Price (USD/Unit) of Manufacturers (2021-2026) Table 11. Global Biosimilar Monoclonal Antibodies Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application Table 14. Global Biosimilar Monoclonal Antibodies Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Biosimilar Monoclonal Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Celltrion Company Information Table 19. Celltrion Business Overview Table 20. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 21. Celltrion Biosimilar Monoclonal Antibodies Product Portfolio Table 22. Celltrion Recent Developments Table 23. Pfizer (Hospira) Company Information Table 24. Pfizer (Hospira) Business Overview Table 25. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 26. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio Table 27. Pfizer (Hospira) Recent Developments Table 28. 3SBIO Company Information Table 29. 3SBIO Business Overview Table 30. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 31. 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio Table 32. 3SBIO Recent Developments Table 33. Novartis (Sandoz) Company Information Table 34. Novartis (Sandoz) Business Overview Table 35. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 36. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio Table 37. Novartis (Sandoz) Recent Developments Table 38. Dr Reddy’s Company Information Table 39. Dr Reddy’s Business Overview Table 40. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 41. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio Table 42. Dr Reddy’s Recent Developments Table 43. Celgen Biopharma Company Information Table 44. Celgen Biopharma Business Overview Table 45. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 46. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio Table 47. Celgen Biopharma Recent Developments Table 48. Cadila Healthcare Company Information Table 49. Cadila Healthcare Business Overview Table 50. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 51. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio Table 52. Cadila Healthcare Recent Developments Table 53. Hisun Pharma Company Information Table 54. Hisun Pharma Business Overview Table 55. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 56. Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio Table 57. Hisun Pharma Recent Developments Table 58. Torrent Pharmaceuticals Company Information Table 59. Torrent Pharmaceuticals Business Overview Table 60. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 61. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio Table 62. Torrent Pharmaceuticals Recent Developments Table 63. Global Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 64. Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 65. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2021-2026) Table 66. Global Biosimilar Monoclonal Antibodies Sales by Region (2027-2032) & (K Units) Table 67. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2027-2032) Table 68. Global Biosimilar Monoclonal Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 69. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2021-2026) Table 70. Global Biosimilar Monoclonal Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 71. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2027-2032) Table 72. North America Biosimilar Monoclonal Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. North America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 74. North America Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 75. North America Biosimilar Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 76. North America Biosimilar Monoclonal Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 77. Europe Biosimilar Monoclonal Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Europe Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 79. Europe Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 80. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 82. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 84. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 85. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 86. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 87. South America Biosimilar Monoclonal Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. South America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 89. South America Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 90. South America Biosimilar Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 91. South America Biosimilar Monoclonal Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 92. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 94. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 95. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 96. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 97. Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 98. Global Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 99. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2026) Table 100. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2027-2032) Table 101. Global Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 102. Global Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 103. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2026) Table 104. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2027-2032) Table 105. Global Biosimilar Monoclonal Antibodies Price by Type (2021-2026) & (USD/Unit) Table 106. Global Biosimilar Monoclonal Antibodies Price by Type (2027-2032) & (USD/Unit) Table 107. Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 108. Global Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 109. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2026) Table 110. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2027-2032) Table 111. Global Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 112. Global Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 113. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2026) Table 114. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2027-2032) Table 115. Global Biosimilar Monoclonal Antibodies Price by Application (2021-2026) & (USD/Unit) Table 116. Global Biosimilar Monoclonal Antibodies Price by Application (2027-2032) & (USD/Unit) Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Biosimilar Monoclonal Antibodies Distributors List Table 120. Biosimilar Monoclonal Antibodies Customers List Table 121. Biosimilar Monoclonal Antibodies Industry Trends Table 122. Biosimilar Monoclonal Antibodies Industry Drivers Table 123. Biosimilar Monoclonal Antibodies Industry Restraints Table 124. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Biosimilar Monoclonal Antibodies Product Image Figure 5. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Biosimilar Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 7. Global Biosimilar Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 8. Global Biosimilar Monoclonal Antibodies Average Price (USD/Unit) & (2021-2032) Figure 9. Infliximab Product Image Figure 10. Rituximab Product Image Figure 11. Trastuzumab Product Image Figure 12. Adalimumab Product Image Figure 13. Other Product Image Figure 14. Oncology Product Image Figure 15. Autoimmune Disease Product Image Figure 16. Other Product Image Figure 17. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Biosimilar Monoclonal Antibodies Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Biosimilar Monoclonal Antibodies Sales by Region in 2025 Figure 23. Global Biosimilar Monoclonal Antibodies Revenue by Region in 2025 Figure 24. North America Biosimilar Monoclonal Antibodies Market Size by Country in 2025 Figure 25. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 26. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2021-2032) Figure 27. United States Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Biosimilar Monoclonal Antibodies Market Size by Country in 2025 Figure 31. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 32. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2021-2032) Figure 33. Germany Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Country in 2025 Figure 44. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2021-2032) Figure 46. China Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Biosimilar Monoclonal Antibodies Market Size by Country in 2025 Figure 55. South America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 56. South America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2021-2032) Figure 57. Brazil Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country in 2025 Figure 61. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2021-2032) Figure 63. Egypt Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Biosimilar Monoclonal Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2032) Figure 69. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2032) Figure 70. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Type (2021-2032) Figure 71. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2032) Figure 72. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2032) Figure 73. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Application (2021-2032) Figure 74. Biosimilar Monoclonal Antibodies Value Chain Figure 75. Biosimilar Monoclonal Antibodies Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges

Scope & coverage.

Types
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Adalimumab
  • Other
Applications
  • Oncology
  • Autoimmune Disease
  • Other
Companies covered
  • Celltrion
  • Pfizer (Hospira)
  • 3SBIO
  • Novartis (Sandoz)
  • Dr Reddy’s
  • Celgen Biopharma
  • Cadila Healthcare
  • Hisun Pharma
  • Torrent Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Biosimilar Monoclonal Antibodies Market Size (2021-2032)
  4. 2.2.2 Global Biosimilar Monoclonal Antibodies Sales (2021-2032)
  5. 2.2.3 Global Biosimilar Monoclonal Antibodies Market Average Price (2021-2032)
  6. 2.3 Biosimilar Monoclonal Antibodies by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Infliximab
  9. 2.3.3 Rituximab
  10. 2.3.4 Trastuzumab
  11. 2.3.5 Adalimumab
  12. 2.3.6 Other
  13. 2.4 Biosimilar Monoclonal Antibodies by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Oncology
  16. 2.4.3 Autoimmune Disease
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Biosimilar Monoclonal Antibodies Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Biosimilar Monoclonal Antibodies Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Biosimilar Monoclonal Antibodies Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Biosimilar Monoclonal Antibodies Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application
  8. 3.8 Global Manufacturers of Biosimilar Monoclonal Antibodies, Established Date
  9. 3.9 Global Biosimilar Monoclonal Antibodies Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Celltrion
  2. 4.1.1 Celltrion Company Information
  3. 4.1.2 Celltrion Business Overview
  4. 4.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
  6. 4.1.5 Celltrion Recent Developments
  7. 4.2 Pfizer (Hospira)
  8. 4.2.1 Pfizer (Hospira) Company Information
  9. 4.2.2 Pfizer (Hospira) Business Overview
  10. 4.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
  12. 4.2.5 Pfizer (Hospira) Recent Developments
  13. 4.3 3SBIO
  14. 4.3.1 3SBIO Company Information
  15. 4.3.2 3SBIO Business Overview
  16. 4.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
  18. 4.3.5 3SBIO Recent Developments
  19. 4.4 Novartis (Sandoz)
  20. 4.4.1 Novartis (Sandoz) Company Information
  21. 4.4.2 Novartis (Sandoz) Business Overview
  22. 4.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
  24. 4.4.5 Novartis (Sandoz) Recent Developments
  25. 4.5 Dr Reddy’s
  26. 4.5.1 Dr Reddy’s Company Information
  27. 4.5.2 Dr Reddy’s Business Overview
  28. 4.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
  30. 4.5.5 Dr Reddy’s Recent Developments
  31. 4.6 Celgen Biopharma
  32. 4.6.1 Celgen Biopharma Company Information
  33. 4.6.2 Celgen Biopharma Business Overview
  34. 4.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
  36. 4.6.5 Celgen Biopharma Recent Developments
  37. 4.7 Cadila Healthcare
  38. 4.7.1 Cadila Healthcare Company Information
  39. 4.7.2 Cadila Healthcare Business Overview
  40. 4.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
  42. 4.7.5 Cadila Healthcare Recent Developments
  43. 4.8 Hisun Pharma
  44. 4.8.1 Hisun Pharma Company Information
  45. 4.8.2 Hisun Pharma Business Overview
  46. 4.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
  48. 4.8.5 Hisun Pharma Recent Developments
  49. 4.9 Torrent Pharmaceuticals
  50. 4.9.1 Torrent Pharmaceuticals Company Information
  51. 4.9.2 Torrent Pharmaceuticals Business Overview
  52. 4.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
  54. 4.9.5 Torrent Pharmaceuticals Recent Developments
5 Global Biosimilar Monoclonal Antibodies Market Scenario by Region
  1. 5.1 Global Biosimilar Monoclonal Antibodies Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2021-2032
  3. 5.2.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2021-2026
  4. 5.2.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2027-2032
  5. 5.3 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2021-2032
  6. 5.3.1 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2021-2026
  7. 5.3.2 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2027-2032
  8. 5.4 North America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
  9. 5.4.1 North America Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  11. 5.4.3 North America Biosimilar Monoclonal Antibodies Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
  16. 5.5.1 Europe Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  18. 5.5.3 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
  41. 5.7.1 South America Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  43. 5.7.3 South America Biosimilar Monoclonal Antibodies Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2032)
  2. 6.1.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2032)
  4. 6.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032)
  5. 6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Biosimilar Monoclonal Antibodies Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2032)
  2. 7.1.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2032)
  4. 7.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032)
  5. 7.2.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Biosimilar Monoclonal Antibodies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
  2. 8.1.1 Biosimilar Monoclonal Antibodies Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Biosimilar Monoclonal Antibodies Production Mode & Process
  5. 8.2 Biosimilar Monoclonal Antibodies Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Biosimilar Monoclonal Antibodies Distributors
  8. 8.2.3 Biosimilar Monoclonal Antibodies Customers
9 Global Biosimilar Monoclonal Antibodies Analyzing Market Dynamics
  1. 9.1 Biosimilar Monoclonal Antibodies Industry Trends
  2. 9.2 Biosimilar Monoclonal Antibodies Industry Drivers
  3. 9.3 Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
  4. 9.4 Biosimilar Monoclonal Antibodies Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst